60 Degrees Pharmaceuticals (SCTP) Q4 2025 earnings summary

Executive summary

• Specialty pharmaceutical company focused on infectious diseases, with Arakoda® (tafenoquine) approved for malaria prevention and a pipeline targeting vector-borne, fungal, and viral diseases.

• 2025 saw expanded clinical programs for babesiosis, new product launches, and multiple capital raises through offerings and ATM agreements.

• Company operates with a small team, leveraging partnerships and licensing to reduce development costs.

Financial highlights

• Net product revenues for 2025 were $1.01M, up 65% from $0.61M in 2024, driven by increased Arakoda sales and price increases.

• Gross profit was $0.22M (22.3% margin), down from $0.22M (36.7% margin) in 2024, due to higher inventory write-offs.

• Research revenues rose to $0.40M from $0.07M, mainly from USAMMDA and University of Kentucky contracts.

• Operating expenses decreased 16% to $8.39M, with R&D down 58% to $2.11M and G&A up 25% to $6.28M.

• Net loss attributable to the company was $7.37M, improved from $7.95M in 2024.

• Cash and equivalents at year-end were $1.51M, with a going concern warning due to recurring losses and limited cash runway.

Outlook and guidance

• Sufficient cash runway projected through September 2026, assuming no additional capital raises.

• Focus on expanding Arakoda sales, progressing babesiosis clinical trials, and seeking regulatory approvals for new indications.

• Ongoing efforts to improve gross margins and operational efficiency.